Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma-Reference-Cited by-同舟云学术

Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma

Published:2024-06-24 Issue:4 Volume:5 Page:896-899
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Alqahtani Abdullah N. M.¹,Jayne Sandrine¹^ORCID,Ahearne Matthew J.¹²,Trethewey Christopher S.¹³,Duraisingham Sai S.⁴,Lehmann Susann⁵,Cowley Caroline M.⁶,Dyer Martin J. S.¹²,Walter Harriet S.¹⁷^ORCID

Affiliation:

1. The Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, Department of Genetics and Genome Biology, University of Leicester Leicester UK

2. Department of Haematology University Hospitals Leicester Leicester UK

3. Cancer Molecular Diagnostic Laboratory (CMDL) University of Cambridge Cambridge UK

4. Department of Immunology University Hospitals Leicester Leicester UK

5. Institute for Precision Health, Leicester Drug Discovery and Diagnostics, University of Leicester Leicester UK

6. Department of Genetics and Genome Biology Leicester Molecular Diagnostics Leicester Cancer Research Centre, University of Leicester Leicester UK

7. Department of Oncology University Hospitals Leicester Leicester UK

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.966

Reference15 articles.

1. Bruton Tyrosine Kinase Inhibitors

2. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

3. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

4. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition

5. Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma